Daewoong Pharma (069620) — Working Capital to Net Assets Ratio
Daewoong Pharma (069620) has a Working Capital to Net Assets ratio of 10.5% as of September 2025. Working capital of ₩105.61 Billion (current assets of ₩789.51 Billion minus current liabilities of ₩683.90 Billion) is measured against net assets of ₩1.00 Trillion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 069620 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Daewoong Pharma Working Capital to Net Assets (2013–2024)
This chart shows how Daewoong Pharma's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 10.5%, reflecting working capital of ₩105.61 Billion against net assets of ₩1.00 Trillion KRW. See 069620 defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Daewoong Pharma (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Daewoong Pharma from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 069620 market cap.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -1.8% | ₩-16.62 Billion | ₩926.98 Billion | ₩612.79 Billion | ₩629.42 Billion | ▲ +36.0 pp |
| 2023 | -37.8% | ₩-303.19 Billion | ₩802.97 Billion | ₩392.35 Billion | ₩695.53 Billion | ▼ -48.0 pp |
| 2022 | 10.3% | ₩76.14 Billion | ₩741.22 Billion | ₩548.97 Billion | ₩472.83 Billion | ▲ +1.8 pp |
| 2021 | 8.5% | ₩59.74 Billion | ₩702.41 Billion | ₩520.40 Billion | ₩460.66 Billion | ▼ -20.5 pp |
| 2020 | 29.0% | ₩201.60 Billion | ₩695.25 Billion | ₩528.35 Billion | ₩326.75 Billion | ▼ -12.5 pp |
| 2019 | 41.5% | ₩264.18 Billion | ₩635.92 Billion | ₩526.26 Billion | ₩262.08 Billion | ▲ +17.1 pp |
| 2018 | 24.4% | ₩148.27 Billion | ₩607.81 Billion | ₩515.67 Billion | ₩367.40 Billion | ▼ -15.2 pp |
| 2017 | 39.6% | ₩250.08 Billion | ₩631.54 Billion | ₩518.13 Billion | ₩268.05 Billion | ▼ -7.5 pp |
| 2016 | 47.1% | ₩284.63 Billion | ₩604.55 Billion | ₩507.46 Billion | ₩222.83 Billion | ▼ -5.3 pp |
| 2015 | 52.3% | ₩303.67 Billion | ₩580.24 Billion | ₩453.10 Billion | ₩149.44 Billion | ▼ -18.8 pp |
| 2014 | 71.2% | ₩324.11 Billion | ₩455.51 Billion | ₩403.79 Billion | ₩79.68 Billion | ▲ +19.8 pp |
| 2013 | 51.4% | ₩224.92 Billion | ₩437.96 Billion | ₩312.12 Billion | ₩87.20 Billion | — |